| ADRB3 Protein |
|---|
| Protein Name | Adrenoceptor Beta 3 |
| Gene | [ADRB3](https://www.ncbi.nlm.nih.gov/gene/155) |
| UniProt ID | [P13945](https://www.uniprot.org/uniprot/P13945) |
| Molecular Weight | ~64 kDa |
| Subcellular Localization | Cell membrane (plasma membrane) |
| Protein Family | GPCR family (Class A rhodopsin-like) |
| Chromosome Location | 8p11.23 |
ADRB3 (Adrenoceptor Beta 3), also known as β3-adrenergic receptor, is a G-protein coupled receptor (GPCR) encoded by the ADRB3 gene located on chromosome 8p11.23. Unlike β1 and β2 adrenergic receptors, which are widely expressed in the heart and lungs respectively, ADRB3 has a distinct tissue distribution with high expression in adipose tissue, the gastrointestinal tract, and the urinary bladder [1]. The receptor plays crucial roles in regulating lipolysis, thermogenesis, smooth muscle relaxation, and metabolic homeostasis.
Recently, research has revealed important connections between ADRB3 signaling and neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), where metabolic dysfunction and autonomic impairments are prominent features [2]. The β3-adrenergic receptor has emerged as a promising therapeutic target for addressing neuroinflammation, metabolic dysregulation, and autonomic dysfunction in these conditions.
The noradrenergic system, which utilizes norepinephrine (NE) and epinephrine as neurotransmitters/hormones, plays a critical role in modulating neuroinflammation, metabolism, and autonomic function—all processes central to neurodegenerative disease pathogenesis. ADRB3 represents an underexplored component of this system with significant therapeutic potential.
ADRB3 possesses the classic seven-transmembrane domain architecture common to all GPCRs, with several unique structural features:
¶ Transmembrane Domains
- Seven α-helices (TM1-TM7): Span the plasma membrane at angles of ~20-35°
- Conserved motifs:
- DRY motif (Asp-Arg-Tyr) at TM3/ICL2 boundary
- NPxxY motif in TM7
- CWxP motif in TM6
- Ligand binding pocket: Located within the transmembrane bundle
¶ Extracellular Domains
- N-terminus: Extracellular domain of moderate length (~40 amino acids), N-glycosylated
- Three extracellular loops (ECL1-ECL3):
- ECL1: ~15 amino acids
- ECL2: ~35-40 amino acids (largest), involved in ligand recognition
- ECL3: ~10-15 amino acids
¶ Intracellular Domains
- Three intracellular loops (ICL1-ICL3):
- ICL2: Critical for G protein coupling specificity
- ICL3: Longest, contains Gs coupling determinants
- C-terminus: Intracellular domain (~60 amino acids), contains phosphorylation sites for desensitization
ADRB3 exhibits several distinctive characteristics [3]:
Ligand Binding Pocket:
- Differs from β1/β2 adrenergic receptors in amino acid composition
- Accounts for selective agonist responses (e.g., mirabegron)
- Provides distinct pharmacological profile
- Results in resistance to certain β-blockers (e.g., propranolol)
G Protein Coupling:
- Primarily couples to Gs proteins → adenylyl cyclase activation → cAMP production
- Can also couple to Gi/o proteins in certain tissues
- Less efficient coupling than β1/β2 receptors
N-glycosylation Sites:
- Multiple N-linked glycosylation sites in N-terminus
- Affects receptor trafficking and cell surface expression
Palmitoylation:
- C-terminal cysteine for membrane anchoring
- Affects receptor localization and function
Recent advances in GPCR structural biology have enabled detailed understanding:
- Cryo-EM structures: High-resolution structures of β2-adrenergic receptor as template
- Molecular dynamics: Simulations of ligand binding and conformational changes
- Mutagenesis studies: Identification of key binding site residues
ADRB3 primarily couples to Gs proteins, leading to activation of adenylyl cyclase and increased cAMP production [4]:
Norepinephrine/Epinephrine → ADRB3 → Gs protein → Adenylyl cyclase
↓
cAMP production
↓
PKA activation
↓
Multiple cellular responses
ADRB3 can also couple to Gi/o proteins in certain tissues, leading to:
- Inhibition of adenylyl cyclase
- Modulation of ion channels
- Activation of MAPK pathways
¶ Lipolysis and Thermogenesis
ADRB3 is the primary regulator of lipolysis in white adipose tissue [5]:
- Stimulates lipolysis: Activation increases hormone-sensitive lipase (HSL) activity
- Lipid mobilization: Releases free fatty acids into circulation
- Energy supply: Provides fuel during fasting and exercise
- Non-shivering thermogenesis: Essential for maintaining body temperature
- UCP1 expression: Promotes uncoupling protein 1 (UCP1) expression
- Energy expenditure: Contributes to whole-body energy homeostasis
- BAT activation: Counteracts obesity and metabolic syndrome
- Beiging process: Promotes browning of white adipocytes
- Thermogenic capacity: Increases energy expenditure
- Therapeutic potential: Target for metabolic diseases
In the gastrointestinal tract, ADRB3 regulates [6]:
- Smooth muscle relaxation: Modulates intestinal motility and tone
- Sphincter function: Affects pyloric and ileocecal sphincters
- Secretion: Influences fluid and electrolyte transport
- Splanchnic blood flow: Controls blood distribution during digestion
- Gut motility: Reduced contractile activity via β3 signaling
ADRB3 is the predominant β-adrenergic receptor in the bladder detrusor muscle [7]:
- Bladder relaxation: Mediates storage phase relaxation
- Urinary continence: Contributes to urinary retention prevention
- Overactive bladder: Therapeutic target for bladder dysfunction
- Micturition cycle: Modulates filling and voiding phases
The receptor influences glucose and lipid metabolism:
- Insulin sensitivity: Modulates insulin secretion and action
- Gluconeogenesis: Influences hepatic glucose production
- Pancreatic function: Affects β-cell function
- Lipogenesis: Regulates triglyceride synthesis
- Cholesterol metabolism: Modulates lipid homeostasis
- Adipocyte differentiation: Regulates adipocyte development
- Food intake: Central effects on appetite
- Energy expenditure: Thermogenic effects
- Body weight: Long-term energy homeostasis
ADRB3 has a distinct expression pattern:
- Adipose tissue: Highest expression (white, brown, beige)
- Gastrointestinal tract: Stomach, small intestine, colon
- Urinary bladder: Detrusor muscle
- Heart: Low expression compared to β1/β2
- Skeletal muscle: Low to moderate expression
- Liver: Low expression
- Hypothalamus: Moderate expression, particularly arcuate nucleus
- Brainstem: Limited expression
- Spinal cord: Dorsal horn neurons
- Blood-brain barrier: Endothelial cells
ADRB3 signaling has emerged as a significant pathway in Alzheimer's disease pathogenesis [8]:
ADRB3 dysfunction contributes to impaired brain energy metabolism:
- Brain glucose metabolism: ADRB3 affects peripheral glucose homeostasis, indirectly impacting brain energy supply
- Altered lipid metabolism: Dysregulated lipid metabolism in neurons and glia
- Mitochondrial dysfunction: β3-adrenergic effects on mitochondrial biogenesis
- Insulin resistance: Links between β3 signaling and brain insulin resistance
β3-adrenergic signaling modulates neuroinflammation through [9]:
- Microglial activation: Anti-inflammatory effects in microglia
- Cytokine regulation: Modulates TNF-α, IL-1β, IL-6 production
- Astrocyte modulation: Affects astrocyte activation and function
- T-cell infiltration: Modulates adaptive immune responses
ADRB3 agonists show promise in AD:
- Mirabegron: Enhances memory function in preclinical models
- Synaptic plasticity: Improved LTP and memory consolidation
- Amyloid-β effects: Reduced Aβ toxicity in models
- Tau pathology: Potential effects on tau phosphorylation
ADRB3 plays a role in autonomic dysfunction in AD:
- Orthostatic hypotension: Common in AD patients
- Gastrointestinal dysmotility: Contributes to nutritional issues
- Urinary dysfunction: Bladder overactivity
ADRB3 plays important roles in Parkinson's disease, particularly autonomic dysfunction [10]:
PD patients commonly exhibit:
- Urinary dysfunction: Overactive bladder, urgency, frequency
- Gastrointestinal dysmotility: Delayed gastric emptying, constipation
- Orthostatic hypotension: Autonomic failure
- Sexual dysfunction: Autonomic involvement
β3-adrenergic signaling offers neuroprotective effects:
- Dopaminergic neuron survival: Protection of substantia nigra neurons
- Mitochondrial function: Enhanced mitochondrial biogenesis
- Neuroinflammation reduction: Anti-inflammatory effects
- Oxidative stress: Antioxidant responses
ADRB3 modulators may help in PD:
- Urinary symptoms: Mirabegron approved for overactive bladder
- Gastrointestinal function: Potential for motility disorders
- Neuroprotection: Disease-modifying potential
- Non-motor symptoms: Target autonomic dysfunction
ADRB3 is particularly relevant in MSA:
- Autonomic failure: Prominent autonomic dysfunction
- Orthostatic hypotension: Severe orthostatic intolerance
- Urinary dysfunction: Bladder involvement
ADRB3 is a validated target for metabolic diseases [11]:
- Genetic variants: Trp64Arg associated with weight gain
- Fat distribution: Influence on body fat distribution
- Thermogenic response: Affected thermogenic capacity
- Insulin resistance: Contributes to insulin resistance
- Glucose tolerance: Impaired glucose tolerance
- Dyslipidemia: Altered lipid profiles
ADRB3 affects cardiovascular function:
- Heart rate: Modest effects compared to β1
- Blood pressure: Complex interactions
- Cardiac output: Limited direct cardiac effects
| Drug |
Status |
Indications |
Mechanism |
| Mirabegron |
Approved |
Overactive bladder |
β3-selective agonist |
| CL-316,243 |
Research |
Obesity, diabetes |
β3-selective agonist |
| Solabegron |
Clinical trials |
IBS, OAB |
β3-selective agonist |
| Vibegron |
Approved |
Overactive bladder |
β3-selective agonist |
| ritobegron |
Research |
Metabolic disorders |
β3-selective agonist |
- FDA approved: For overactive bladder (2012)
- Dose: 25-50 mg daily
- Efficacy: Reduces urinary frequency, urgency
- Side effects: Hypertension, headache
- Preclinical: Extensive studies in obesity models
- Effects: Increased thermogenesis, reduced adiposity
- Challenge: Limited human translation
β3-selective antagonists under development for:
- Cardiac conditions: Heart failure
- Metabolic syndrome: Insulin resistance
- Bladder dysfunction: In combination therapy
- Phase 1/2 trials: For COPD and metabolic diseases
- Dual targeting: Broader therapeutic potential
Polymorphisms in the ADRB3 gene affect drug response and disease risk [12]:
-
Trp64Arg (rs4994): Arg64 variant associated with:
- Reduced receptor function
- Obesity susceptibility
- Altered thermogenic response
- Type 2 diabetes risk
-
Promoter variants: Affect receptor expression levels
-
Other SNPs: Various functional implications
- Drug response: Variability in response to β3 agonists
- Disease risk: Association with obesity, diabetes
- Personalized medicine: Pharmacogenomic applications
- ADRB3 KO mice: Reduced lipolysis, thermogenesis defects
- Phenotype: Obesity-prone, metabolic dysfunction
- Studies: Revealed β3-specific functions
- Overexpression: Enhanced thermogenesis
- Conditional KO: Tissue-specific deletion
- Humanized: Expressing human ADRB3
- Obesity models: Diet-induced obesity
- Diabetes models: STZ-induced diabetes
- PD models: MPTP, α-synuclein models
- AD models: APP/PS1 with β3 modulation
- ADRB3 expression: On peripheral blood mononuclear cells
- Plasma NE levels: Reflect sympathetic activity
- Metabolic markers: Lipid profile, glucose
- SNP genotyping: Trp64Arg and other variants
- Haplotype analysis: Predictive of drug response
- Brain-penetrant agonists: CNS-active β3 agonists
- Biased agonists: Pathway-selective signaling
- Allosteric modulators: Novel mechanism
- β2/β3 agonists: Dual targeting
- With other mechanisms: Multi-target approaches
- Response prediction: Genetic and expression markers
- Disease monitoring: Therapeutic efficacy markers